PRAC has shown efficacy in treating several types of cancer, most notably breast cancer and ovarian cancer. Clinical trials are also exploring its use in other cancers, such as prostate cancer and pancreatic cancer. The effectiveness of PARP inhibitors in these cancers often depends on the presence of specific genetic mutations, such as those in the BRCA1 or BRCA2 genes.
